These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 2859279)
21. Basic principles of rapid neuroleptization. Mason AS; Granacher RP Dis Nerv Syst; 1976 Oct; 37(10):547-51. PubMed ID: 9267 [No Abstract] [Full Text] [Related]
22. Depot neuroleptics: side effects and safety. Marder SR J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089 [TBL] [Abstract][Full Text] [Related]
23. Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Casey DE Br J Psychiatry Suppl; 1996 May; (29):32-9. PubMed ID: 8733821 [No Abstract] [Full Text] [Related]
24. Current status of institutionalized mental health patients' right to refuse psychotropic drugs. Kemna DJ J Leg Med; 1985 Mar; 6(1):107-38. PubMed ID: 2860193 [No Abstract] [Full Text] [Related]
26. Tardive dyskinesia: are first signs reversible? Quitkin F; Rifkin A; Gochfeld L; Klein DF Am J Psychiatry; 1977 Jan; 134(1):84-7. PubMed ID: 12666 [TBL] [Abstract][Full Text] [Related]
27. Decreased extrapyramidal side effects and polypsichopharmacy in family practice outpatients. Holt RJ Bol Asoc Med P R; 1983 Aug; 75(8):351-2. PubMed ID: 6139115 [No Abstract] [Full Text] [Related]
28. Drug history and tardive dyskinesia. Smith RC; Strizich M; Klass D Am J Psychiatry; 1978 Nov; 135(11):1402-3. PubMed ID: 30289 [No Abstract] [Full Text] [Related]
29. Extrapyramidal side effects: a historical perspective. Rifkin A J Clin Psychiatry; 1987 Sep; 48 Suppl():3-6. PubMed ID: 2887555 [TBL] [Abstract][Full Text] [Related]
30. The efficacy, safety, and tolerability of antipsychotics in the elderly. Maixner SM; Mellow AM; Tandon R J Clin Psychiatry; 1999; 60 Suppl 8():29-41. PubMed ID: 10335669 [TBL] [Abstract][Full Text] [Related]
31. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060 [TBL] [Abstract][Full Text] [Related]
32. Pathophysiology of antipsychotic drug-induced movement disorders. Casey DE J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109 [TBL] [Abstract][Full Text] [Related]
34. Dose response of prophylactic antipsychotics. Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195 [TBL] [Abstract][Full Text] [Related]
35. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics. Moleman P; Schmitz PJ; Ladee GA J Clin Psychiatry; 1982 Dec; 43(12):492-6. PubMed ID: 7161250 [TBL] [Abstract][Full Text] [Related]
36. [Neuroleptics and the extrapyramidal system]. Haase HJ Arzneimittelforschung; 1978; 28(9):1536-7. PubMed ID: 38814 [No Abstract] [Full Text] [Related]
37. [Current status of our knowledge of the neurotropic side effects of neuroleptic drugs]. Sabbatini F; Pinessi L; Gentile S; De Mattei M; Portaleone P Minerva Psichiatr; 1983; 24(4):145-53. PubMed ID: 6145083 [No Abstract] [Full Text] [Related]
38. Pharmacokinetic parameters of bromperidol in Korean subjects. Lee SY; Kim YG; Kim HG; Kim JW Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic drug monitoring of psychotropic drugs in children. Morselli PL; Bianchetti G; Dugas M Pediatr Pharmacol (New York); 1983; 3(3-4):149-56. PubMed ID: 6146122 [TBL] [Abstract][Full Text] [Related]
40. [When does the extrapyramidal syndrome become an adverse reaction to major psychotropic drugs? ]. Csiky K Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1978; 23(2):131-4. PubMed ID: 30159 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]